Adverum Biotechnologies Inc

NASDAQ:ADVMUnited States

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.

Contact Information

Headquarters

100 Cardinal WayREDWOOD CITY, CA, United States 94063

Phone

650-649-1004

Fax

650-329-8151

Executives

Independent Chairman of the Board

Patrick Machado

President, Chief Executive Officer, Director

Laurent Fischer

Chief Financial Officer

Linda Rubinstein

Chief Operating Officer

Kishor Soparkar

Chief Technology Officer

Andrew Ramelmeier